Orem, Utah
We conduct high quality psychiatric clinical trials with a specialty in psychedelic medicines.
Questions? Call or text 801-871-5516
4 studies now enrolling in Orem, Utah
Definium Therapeutics
Ascend looks at whether a single dose of DT120 (formerly MM120, a form of LSD) reduces symptoms of depression compared with placebo. Participants may be offered additional doses later in the study.
Transcend
For adults living with Post Traumatic Stress Disorder (PTSD)
The purpose of this study is to assess the efficacy, safety, and tolerability of TSND-201 for the treatment of PTSD symptoms compared to placebo.
Reunion
The purpose of this study is to determine if treatment with a single dose of RE104 reduces anxiety symptoms in participants with Generalized Anxiety Disorder (GAD) as compared to placebo.
LB Pharmaceuticals
For adults with a diagnosis of Bipolar I Disorder currently experiencing a Major Depressive Episode (MDE).
Not sure which study fits? A short self-assessment can help you narrow it down.
Check YourselfAscend looks at whether a single dose of DT120 (formerly MM120, a form of LSD) reduces symptoms of depression compared with placebo. Participants may be offered additional doses later in the study.
This study is sponsored by Definium Therapeutics, formerly MindMed.
For adults living with Post Traumatic Stress Disorder (PTSD)
The purpose of this study is to assess the efficacy, safety, and tolerability of TSND-201 for the treatment of PTSD symptoms compared to placebo.
This study is sponsored by Transcend Therapeutics, Inc.
The purpose of this study is to determine if treatment with a single dose of RE104 reduces anxiety symptoms in participants with Generalized Anxiety Disorder (GAD) as compared to placebo.
This study is sponsored by Reunion.
For adults with a diagnosis of Bipolar I Disorder currently experiencing a Major Depressive Episode (MDE).
The goal of this study is to evaluate the efficacy, safety, and tolerability of LB-102, compared to placebo, in treating depressive symptoms associated with Bipolar I Disorder.
This study is sponsored by LB Pharmaceuticals.
New to clinical trials? Start with our beginner's guide
Ascend looks at whether DT120 (D-lysergic acid diethylamide D-tartrate, formerly called MM120) helps reduce symptoms of depression, compared with . It has two parts:
This study is sponsored by Definium Therapeutics, formerly MindMed.
You may be eligible to participate in this study if you:
Our team will go over the full requirements with you in a short phone call.
Curious what participating actually involves?Understanding Psychedelic-Assisted Therapy Research for DepressionRead the guide · 3 minIf you are interested in participating in this clinical trial, please call our friendly staff at 801-871-5516 today. You can also fill out the contact form below.
For adults living with Post Traumatic Stress Disorder (PTSD)
The purpose of this study is to assess the efficacy, safety, and tolerability of TSND-201 for the treatment of PTSD symptoms compared to placebo.
This study is sponsored by Transcend Therapeutics, Inc.
The purpose of this study is to determine if treatment with a single dose of RE104 reduces anxiety symptoms in participants with Generalized Anxiety Disorder (GAD) as compared to placebo.
This study is sponsored by Reunion.
For adults with a diagnosis of Bipolar I Disorder currently experiencing a Major Depressive Episode (MDE).
The goal of this study is to evaluate the efficacy, safety, and tolerability of LB-102, compared to placebo, in treating depressive symptoms associated with Bipolar I Disorder.
This study is sponsored by LB Pharmaceuticals.
Still have a question? Our team is happy to walk you through anything, including whether a study might be a fit.
Inner Space Research is a mental health clinical research center in Orem, Utah. We conduct clinical trials that study new treatments for conditions such as depression, anxiety, PTSD, and related mental health challenges. Our goal is to help expand safe, evidence-based treatment options while providing a supportive and ethical research experience for participants.
A clinical trial is a structured research study that evaluates whether a new therapy, medication, or treatment approach is safe and effective for people. Mental health clinical trials help researchers and regulators understand which treatments work best and who they may help. These studies are an essential step in bringing new therapies to patients.
We conduct clinical trials focused on depression, anxiety disorders, trauma-related conditions, and other psychiatric concerns. Some studies involve emerging therapies being researched in mental health care. Contact our team to see what is currently enrolling.
Each study has specific eligibility criteria based on factors such as age, diagnosis, medical history, and current medications. Our research team will guide you through a confidential screening process to determine whether you may qualify for a study.
No referral is required. You can contact Inner Space Research directly through our website or by phone to learn about enrolling studies and begin the screening process.
There is typically no cost to participate in a clinical trial. Study-related visits, assessments, and treatments are usually provided at no charge. Some studies also offer compensation for time and travel. Details vary by study and will be explained during screening.
Some clinical trials include access to active treatment, while others may involve a placebo or comparison group. The structure of each study is explained during the informed consent process so you can decide whether participation is right for you.
Participant safety is the top priority. All studies follow strict ethical guidelines and are reviewed by regulatory and ethics boards. Participants are carefully monitored by trained clinical staff throughout the study.
Yes. Personal and medical information is handled in accordance with federal privacy laws and research confidentiality standards. Your participation and data are kept secure and confidential.
In many cases, yes. Our team will review your current care and coordinate as appropriate. Participation in research is voluntary, and you may withdraw at any time.
Study timelines vary depending on the protocol. Some trials last a few weeks, while others continue for several months and may include follow-up visits. The full schedule is reviewed with you before enrollment.
We are located in Orem, Utah, and serve participants throughout Utah County, Salt Lake County, and surrounding communities.
You can contact Inner Space Research through our website, complete a study interest form, or call our team directly. We will walk you through eligibility screening, next steps, and answer any questions about participating in a mental health clinical trial.
Inner Space Research is a psychiatry-focused clinical research center in Orem, Utah, led by experienced clinicians and investigators dedicated to advancing innovative mental health treatments.
With decades of combined experience and leadership across hundreds of clinical trials, including research on ketamine and emerging psychedelic-assisted therapies, our team works at the intersection of rigorous science and compassionate care. Our purpose is to expand safe, evidence-based treatment options and contribute to research that is shaping the future of mental health.
CEO and Co-founder
Dr. Steve Thayer, Ph.D. is a clinical psychologist who specializes in psychedelic-assisted therapy practice, training, and research. He began his career in the U.S. Air Force where he led mental health care teams, provided therapeutic and assessment services, and counseled military leadership about community mental health concerns. As an adjunct professor, Dr. Thayer has taught graduate and undergraduate courses in counseling skills, clinical psychology, and personality theory. He has served as the lead therapist on several psychedelic medicine clinical trials and currently consults for Compass Pathways as a mentor to the therapists working on their phase 3 trial of psilocybin for treatment-resistant depression.
Dr. Thayer is the Lead Instructor for Numinus Wellness's psychedelic-assisted therapy certification program and co-hosts the popular podcast, Psychedelic Therapy Frontiers. Dr. Thayer has a private therapy and coaching practice where he helps people resolve the unconscious blocks keeping them from creating the happiness, freedom, and relationships they crave.
Dr. Thayer is the CEO and Co-founder at Inner Space Research, a psychiatry-focused clinical research site in Orem, Utah.
Chief Medical Officer and Co-founder
Dr. Reid Robison, MD, MBA, is a board-certified psychiatrist and clinical researcher with deep expertise in ketamine and psychedelic medicine. He has served as principal investigator on more than 250 CNS clinical trials. Dr. Robison received his first grant to study ketamine in 2010 and, around that time, led the Utah site for a pivotal IV ketamine trial for treatment-resistant depression in collaboration with Janssen.
He has been principal investigator for numerous Phase II–III clinical trials involving Schedule I psychedelic compounds, including psilocybin, LSD, 5-MeO-DMT, and other serotonergic hallucinogens. Dr. Robison is the first author of the September 2025 JAMA Psychiatry paper reporting results from MindMed’s Phase II study of MM120 for generalized anxiety disorder, and a co-author on the Usona Phase II psilocybin study manuscript. He also served as coordinating investigator for the MAPS-sponsored trial of MDMA-assisted psychotherapy for eating disorders.
Dr. Robison previously founded Cedar Clinical Research, one of the top-enrolling Phase II–III psychedelic trial sites, as well as Cedar Psychiatry, a Utah-based mental health clinic network that grew to more than 50,000 patient visits and delivered over 10,000 Spravato and ketamine therapy sessions annually. Additionally, he has served as Medical Director of Center for Change, a leading eating disorder treatment center, since 2018. He is also the co-host of Psychedelic Therapy Frontiers, a widely regarded podcast exploring emerging research, therapeutic models, and best practices in psychedelic medicine. He also serves as adjunct faculty at the University of Utah and is the founder of the nonprofit organizations Polizzi Free Clinic and the Psychedelic Institute.
We’re here to help and happy to answer your questions. Reach out anytime.
Fax (385) 582-0110
404
It may have moved when we rebuilt our site, or the link has a typo. These are good places to start.
Looking for a study? Call or text 801-871-5516.
Our team will be in touch soon. Want to talk sooner? Call or text 801-871-5516.
These are the same validated questionnaires clinicians and researchers use every day. Answer honestly, see your results explained in plain language, and share them with anyone you choose: a friend, a family member, your doctor, or our team.
In crisis? Call or text 988, anytime.
Depression, anxiety, and post-traumatic stress overlap. This runs all three screeners back to back and turns them into one profile showing where your center of gravity sits. It's an informal summary, not a diagnosis.
The most widely used depression screener in clinical care and research. Nine questions about the last two weeks.
About the PHQ-9 & how scoring worksThe Edinburgh Postnatal Depression Scale, the standard screen during pregnancy and the year after birth, when ordinary depression questions about sleep and appetite can mislead. Ten questions about the past seven days.
About the EPDS & how scoring worksA brief, validated measure of anxiety symptoms. Seven questions about the last two weeks.
About the GAD-7 & how scoring worksA self-rating worksheet covering the 14 symptom areas of the Hamilton Anxiety Rating Scale: worry and tension, but also the physical side the GAD-7 never asks about. Fourteen questions about the past week. Not a validated self-report scale.
About the HAM-A & how scoring worksThe standard self-report measure of PTSD symptoms, developed by the U.S. National Center for PTSD. Twenty questions about the last month.
About the PCL-5 & how scoring worksThe standard screen for lifetime manic or hypomanic symptoms, often used to check whether depression may be part of a bipolar pattern. Fifteen questions.
About the MDQ & how scoring worksThe World Health Organization’s six-question screen for adult ADHD: a quick read on whether attention and restlessness symptoms are currently affecting your life. Six questions about the past six months.
About the ASRS & how scoring worksThe standard clinical measure of obsessive-compulsive symptom severity, adapted for self-report. Ten questions, scored separately for obsessions and compulsions.
About the Y-BOCS-SR & how scoring worksThe American Psychiatric Association’s 23-question wide-angle snapshot across 13 mental health domains, a map of what might deserve a closer look. Note: it does not cover trauma or PTSD; use the PCL-5 for that.
About the DSM-XC & how scoring worksIf you have been told “bipolar” by one person and “schizoaffective” by another, the difference comes down to timing: whether unusual experiences ever happened on their own. This walks through that timeline the way a clinician would. Not a scored test, and not a diagnosis.
About this walkthrough & how it reads your answersInner Space Research runs clinical trials of investigational treatments for depression, anxiety, PTSD, and other mental health conditions.
A score here doesn't determine whether you qualify for a study. Only a full evaluation with our clinical team can do that. But it can give you (and us) a useful starting point. If your results suggest you might be a fit, we'd love to hear from you.
Your answers never leave your device. When you finish a questionnaire, your results are encoded directly into a web link. That link is your result. Share it, bookmark it, or close the page and it's gone. We don't store, transmit, or see anything unless you choose to send your results to someone.
Clinicians, friends, and our own prescreening team are welcome to link people directly to any questionnaire. Each questionnaire has its own page you can link to.
These screeners are offered free to our community. They are educational tools: not a diagnosis, not medical advice, and not a determination of eligibility for any research study. No answers are stored or transmitted by this site; your results live only in your browser and in the link you choose to keep or share.
Sources. PHQ-9 and GAD-7: developed by Drs. Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke and colleagues, with an educational grant from Pfizer Inc.; no permission required to reproduce. PCL-5: Weathers, Litz, Keane, Palmieri, Marx, & Schnurr (2013), U.S. National Center for PTSD; public domain. EPDS: Cox, J.L., Holden, J.M., & Sagovsky, R. (1987). Detection of postnatal depression: Development of the 10-item Edinburgh Postnatal Depression Scale. British Journal of Psychiatry, 150, 782–786. MDQ: © 2000 by The University of Texas Medical Branch, reprinted with permission. ASRS v1.1 Screener: © World Health Organization; Kessler et al. (2005). Y-BOCS: adapted for self-report from Goodman et al. (1989), Archives of General Psychiatry, 46, 1006–1011. HAM-A worksheet: a plain-language self-rating adaptation of Hamilton (1959), British Journal of Medical Psychology, 32, 50–55; not a validated self-report scale. DSM-5 Level 1 Cross-Cutting Symptom Measure: © 2013 American Psychiatric Association; this material can be reproduced without permission by researchers and by clinicians for use with their patients. The mood and unusual experiences walkthrough was written by Inner Space Research and is not a scored instrument.
If you are interested in participating in this clinical trial, please call our friendly staff at 801-871-5516 today. You can also fill out the contact form below.
